Literature DB >> 12496215

Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A.

Joanna R Kirman1, Tara Turon, Hua Su, Amy Li, Carl Kraus, John M Polo, John Belisle, Sheldon Morris, Robert A Seder.   

Abstract

The immunogenicity of a plasmid DNA vaccine incorporating Sindbis virus RNA replicase functions (pSINCP) and expressing antigen 85A (Ag85A) from Mycobacterium tuberculosis was compared with a conventional plasmid DNA vector encoding Ag85A. pSINCP-85A was highly immunogenic in mice and gave enhanced long-term protection against M. tuberculosis compared with the conventional vector.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12496215      PMCID： PMC143413          DOI： 10.1128/IAI.71.1.575-579.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  19 in total

1.  Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene.

Authors:  W F Cheng; C F Hung; C Y Chai; K F Hsu; L He; C M Rice; M Ling; T C Wu
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

2.  Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein.

Authors:  J P Gardner; I Frolov; S Perri; Y Ji; M L MacKichan; J zur Megede; M Chen; B A Belli; D A Driver; S Sherrill; C E Greer; G R Otten; S W Barnett; M A Liu; T W Dubensky; J M Polo
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.

Authors:  W W Leitner; H Ying; D A Driver; T W Dubensky; N P Restifo
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

4.  Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters.

Authors:  K I Kamrud; J W Hooper; F Elgh; C S Schmaljohn
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

5.  Cancer therapy using a self-replicating RNA vaccine.

Authors:  H Ying; T Z Zaks; R F Wang; K R Irvine; U S Kammula; F M Marincola; W W Leitner; N P Restifo
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

6.  Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen.

Authors:  K F Hsu; C F Hung; W F Cheng; L He; L A Slater; M Ling; T C Wu
Journal:  Gene Ther       Date:  2001-03       Impact factor: 5.250

7.  DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.

Authors:  L B Lachman; X M Rao; R H Kremer; B Ozpolat; G Kiriakova; J E Price
Journal:  Cancer Gene Ther       Date:  2001-04       Impact factor: 5.987

8.  Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen.

Authors:  C Andersson; P Liljeström; S Ståhl; U F Power
Journal:  FEMS Immunol Med Microbiol       Date:  2000-12

9.  Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.

Authors:  S L Baldwin; C D D'Souza; I M Orme; M A Liu; K Huygen; O Denis; A Tang; L Zhu; D Montgomery; J B Ulmer
Journal:  Tuber Lung Dis       Date:  1999

10.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962
View more
  15 in total

Review 1.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

2.  Enhanced immunogenicity to food-and-mouth disease virus in mice vaccination with alphaviral replicon-based DNA vaccine expressing the capsid precursor polypeptide (P1).

Authors:  Xiaolan Yu; Shaobo Xiao; Liurong Fang; Yunbo Jiang; Huanchun Chen
Journal:  Virus Genes       Date:  2006-12       Impact factor: 2.332

3.  The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Authors:  Lise Brandt; Yasir A W Skeiky; Mark R Alderson; Yves Lobet; Wilfried Dalemans; Oliver C Turner; Randall J Basaraba; Angelo A Izzo; Todd M Lasco; Philip L Chapman; Steven G Reed; Ian M Orme
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis.

Authors:  Steven C Derrick; Amy Li Yang; Sheldon L Morris
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

5.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

6.  Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection.

Authors:  Ying Wu; Joshua S Woodworth; Daniel S Shin; Sheldon Morris; Samuel M Behar
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

7.  Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.

Authors:  Yinling Lin; Taewoo Kwon; John Polo; Yi-Fei Zhu; Stephen Coates; Kevin Crawford; Christine Dong; Mark Wininger; John Hall; Mark Selby; Doris Coit; Angelica Medina-Selby; Colin McCoin; Philip Ng; Debbie Drane; David Chien; Jang Han; Michael Vajdy; Michael Houghton
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

Review 8.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

Review 9.  Next generation: tuberculosis vaccines that elicit protective CD8+ T cells.

Authors:  Samuel M Behar; Joshua S M Woodworth; Ying Wu
Journal:  Expert Rev Vaccines       Date:  2007-06       Impact factor: 5.217

10.  Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.

Authors:  Jia Lu; Chun Wang; Zhiguang Zhou; Ying Zhang; Tingting Cao; Chunwei Shi; Zhenhua Chen; Lingxia Chen; Changxue Cai; Xionglin Fan
Journal:  Clin Dev Immunol       Date:  2011-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.